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Introduction: Denosumab, a fully human anti-RANKL monoclonal 
antibody, reduces the incidence of skeletal-related events in patients 
with bone metastases from solid tumors. We present survival data 
for the subset of patients with lung cancer, participating in the phase 
3 trial of denosumab versus zoledronic acid (ZA) in the treatment 
of bone metastases from solid tumors (except breast or prostate) or 
multiple myeloma.
Methods: Patients were randomized 1:1 to receive monthly subcu-
taneous denosumab 120 mg or intravenous ZA 4 mg. An exploratory 
analysis, using Kaplan–Meier estimates and proportional hazards 
models, was performed for overall survival among patients with 
non–small-cell lung cancer (NSCLC) and SCLC.
Results: Denosumab was associated with improved median overall 
survival versus ZA in 811 patients with any lung cancer (8.9 versus 
7.7 months; hazard ratio [HR] 0.80) and in 702 patients with NSCLC 
(9.5 versus 8.0 months; HR 0.78) (p = 0.01, each comparison). Further 
analysis of NSCLC by histological type showed a median survival of 
8.6 months for denosumab versus 6.4 months for ZA in patients with 
squamous cell carcinoma (HR 0.68; p = 0.035). Incidence of overall 
adverse events was balanced between treatment groups; serious adverse 
events occurred in 66.0% of denosumab-treated patients and 72.9% 
of ZA-treated patients. Cumulative incidence of osteonecrosis of the 
jaw was similar between groups (0.7% denosumab versus 0.8% ZA). 
Hypocalcemia rates were 8.6% with denosumab and 3.8% with ZA.
Conclusion: In this exploratory analysis, denosumab was associated 
with improved overall survival compared with ZA, in patients with 
metastatic lung cancer.
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(J Thorac Oncol. 2012;7: 1823–1829)
Lung cancer, characterized as non–small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC), is the lead-
ing cause of cancer mortality worldwide.1 Advanced NSCLC 
accounts for more than 80% of newly diagnosed cases, and stage 
IV disease is associated with 5-year survival rates of less than 
5%.2 Primary tumors invade the vascular and lymphatic chan-
nels, causing metastatic dissemination to distant sites. Common 
metastatic sites include bone, liver, lung, adrenals, and brain.3
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One of the most frequent sites of metastasis is the bone. 
An estimated 30% to 40% of patients with NSCLC develop 
bone metastases and associated osteoclast-mediated bone 
destruction during the clinical course of the disease.4 Ensuing 
complications, collectively known as skeletal-related events 
(SREs), include pathologic fracture, need for radiation or sur-
gery to the bone, or spinal cord compression.5,6 Hypercalcemia 
of malignancy is also seen more frequently in patients with 
metastatic bone disease. SREs cause pain and decreased qual-
ity of life, with declines in physical, functional, and emotional 
well being.7 Health care costs are also substantial, reported to 
be $28,000 higher over a 24-month period for patients with 
SREs compared with a propensity-matched sample of patients 
without SREs.8
Prevention or delay of SREs may preserve quality of 
life and reduce health care costs. Antiresorptive agents are fre-
quently used for the prevention of SREs in patients with bone 
metastases. The intravenous bisphosphonate zoledronic acid 
(ZA) has been shown to reduce SREs in patients with solid 
tumors, including lung cancer.9–12
An alternative and more recently developed treatment 
strategy is to specifically target RANKL, which is an essential 
mediator of osteoclast function, formation, and survival.13–15 
It is hypothesized that tumor cells in the bone cause increased 
expression of RANKL on osteoclasts and their precursors. 
Excessive RANKL-induced osteoclast activity results in 
resorption and local bone destruction, leading to SREs.16,17
Denosumab, a fully human anti-RANKL monoclonal 
antibody, is approved for the prevention of SREs in patients 
with solid tumors and bone metastases. In a previously 
reported pivotal phase 3 trial in patients with bone metastases 
from solid tumors (other than breast or prostate) or multiple 
myeloma,18 denosumab was shown to be noninferior to ZA 
in delaying time to first SRE. Overall survival was similar 
between the two treatment groups.
Here we present an exploratory analysis of survival 
among a large subset of patients with lung cancer, who par-
ticipated in the previously reported phase 3 trial.18 The objec-
tive of the analysis was to investigate survival in a lung cancer 
population treated with denosumab versus ZA.
MATERIALS AND METHODS
This exploratory analysis was conducted in the sub-
group of patients with lung cancer who participated in the 
international, double-blind, phase 3 trial comparing deno-
sumab versus ZA for the treatment of bone metastases in 
patients with advanced cancer (excluding breast or pros-
tate cancer) or multiple myeloma.18 Key efficacy endpoints 
included the time to first onstudy SRE and time to first and 
subsequent onstudy SREs. Details of the study design and 
results for the primary and key secondary endpoints have 
been previously reported.18
In brief, the trial had an event-driven design: the primary 
analysis was conducted when approximately 745 patients 
experienced an onstudy SRE. Eligible patients were at least 
18 years old, had histologically or cytologically confirmed 
solid tumors (except prostate or breast cancer) or myeloma, 
and radiographic evidence of at least one bone metastasis or 
osteolytic lesion. Key exclusion criteria were prior treatment 
with intravenous bisphosphonates, planned radiation or sur-
gery to bone, and unhealed dental or oral surgery. Patients 
were randomized 1:1 to receive either monthly subcutaneous 
injection of denosumab 120 mg (plus intravenous infusion of 
placebo) or monthly intravenous infusion of ZA 4 mg (plus 
subcutaneous injection of placebo). The ZA dose was adjusted 
for renal impairment. Daily calcium and vitamin D supple-
mentation was strongly recommended for all patients.
For this exploratory analysis, a total of 811 lung cancer 
patients (411 for denosumab and 400 for ZA) were evaluated. 
Baseline characteristics and patient disposition were summa-
rized with descriptive statistics. Overall survival analyses were 
performed separately for all lung cancer patients, patients with 
versus those without visceral metastases, NSCLC patients, 
NSCLC patients by histological type, and SCLC patients. 
Kaplan–Meier (KM) estimates of the survival function were 
graphically displayed, and KM estimates for the median time 
of survival (months) for each treatment group were summa-
rized. Hazard ratios (HR) of denosumab compared with ZA 
for overall survival and corresponding 95% confidence inter-
vals (CI) were estimated using proportional hazards models. 
Adverse events were coded using the Medical Dictionary for 
Regulatory Activities version 12.0 and were summarized with 
patient incidences. Hypocalcemia and osteonecrosis of the 
jaw (ONJ) were identified as adverse events of interest as they 
are associated with inhibition of bone resorption.
RESULTS
Baseline Characteristics
The denosumab and ZA treatment groups were similar 
with respect to baseline characteristics including sex, age, 
ethnicity, and Eastern Cooperative Oncology Group (ECOG) 
status (Table 1). Most patients were men, older than 60 years, 
and white; 80% or more in each group had a baseline ECOG 
status of 0 or 1. In each group, the median time from diagnosis 
of cancer to the first bone metastasis was approximately 
1 month, and the median time from the diagnosis of bone 
metastasis to randomization in the study was approximately 
1.5 months. Approximately 50% in each group had an SRE 
before randomization. Among the patients who experienced 
an SRE before enrollment, radiotherapy to bone was the most 
common type, followed by pathological fracture, surgery to 
bone, and spinal cord compression. The proportion of patients 
with each type of SRE was balanced between treatment 
groups. The majority of patients (89%) had undergone 
prior systemic anticancer therapy. More than 80% of the 
patients in each group had NSCLC, and more than half of 
the NSCLC patients had an adenocarcinoma histological 
type (Table 2). Onstudy cancer chemotherapy is summarized 
in Table 3. Across both lung cancer subtypes and in both 
treatment groups, the majority of patients were treated with 
one or two agents for up to 6 months.
Patient Disposition
The treatment groups were generally similar with 
respect to disposition categories at the time of the primary 
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analysis (Fig. 1). Approximately 87% of patients in the deno-
sumab group compared with 92% in the ZA group discon-
tinued from the study before the primary analysis data cutoff 
date. The most common reasons for discontinuation were 
death, consent withdrawal, and disease progression. Adverse 
events were recorded as the reason for discontinuation in 4% 
of denosumab patients and 6% of ZA patients.
Overall Survival
In 811 patients with any lung cancer, denosumab 
was associated with significantly improved overall median 
survival compared with ZA, with a difference of 1.2 months 
(KM median = 8.9 months versus 7.7 months; HR = 0.80; 
95% CI = 0.67–0.95; p = 0.01) (Fig. 2). Denosumab continued 
to show a significant survival advantage over ZA when overall 
survival was adjusted for relevant baseline covariates (age, 
sex, time from diagnosis of primary cancer to first evidence 
of metastasis, time from diagnosis of primary cancer to first 
bone metastasis, visceral metastasis, and ECOG status) and 
stratified by the randomization stratification factors (previous 
SRE and systematic anticancer therapy) (HR = 0.81; 95% 
CI = 0.68–0.96; p = 0.01). In patients with visceral metastases 
(231 in the denosumab group and 223 in the ZA group), 
denosumab was also associated with improved overall 
median survival, with a difference of 1.2 months (KM 
median = 7.7 months versus 6.4 months; HR = 0.79; 95% 
CI = 0.63–0.98; p = 0.03) (Fig. 3).
Denosumab was associated with significantly improved 
survival in patients with NSCLC, with a difference of 1.5 
months (KM median = 9.5 months versus 8.0 months; HR = 
0.78; 95% CI = 0.65–0.94; p = 0.01) (Fig. 4A). Overall sur-
vival in patients with SCLC was 7.6 months for the deno-
sumab group and 5.1 months for the ZA group, a difference 
of 2.5 months (HR = 0.81; 95% CI = 0.52–1.26; p = 0.36) 
(Fig. 4B). Denosumab-treated patients with squamous cell 
carcinoma also showed improved survival compared with the 
TABLE 1.  Baseline Characteristics of Study Population
Characteristic n (%) or Median (Q1, Q3) Denosumab 
N = 411
Zoledronic Acid 
N = 400
Sex—male 303 (74) 272 (68)
Age (yrs) 60 (54, 68) 61 (54, 69)
Ethnicity—white 364 (89) 353 (88)
ECOG performance status of 0–1 350 (85) 321 (80)
Time from diagnosis of cancer to first bone metastasis (mos)a 0.8 (−0.1, 6.9) 1.0 (0.0, 7.8)
Time from diagnosis of bone metastasis to randomization (mos) 1.5 (0.8, 3.4) 1.6 (0.8, 3.0)
Prior SRE 191 (46) 197 (49)
Prior systemic anticancer therapy 367 (89) 356 (89)
Bone turnover marker: BSAP (µg/L) n 368; 15.5 (11.5, 25.5) 355; 15.6 (11.1, 24.1)
Bone turnover marker: uNTX/creatinine (nmol/mmol) n 340; 37.4 (21.4, 68.3) 339; 35.8 (21.6, 65.1)
aThe lower limit of the interquartile range was a negative number. Some patients complained of bone pain at the initial physician visit; upon investigation, the physician diagnosed cancer.
N, number of patients randomized by actual stratum; ECOG, Eastern Cooperative Oncology Group; BSAP, bone-specific alkaline phosphatase; uNTx, urinary N-telopeptide.
TABLE 2.  Distribution of Patients by Lung Cancer Type
Lung Cancer Type 
n (%)
Denosumab 
N = 411
Zoledronic Acid 
N = 400
NSCLC 350 (85) 352 (88)
 Adenocarcinoma 189 (54) 211 (60)
 Squamous Cell 88 (25) 75 (21)
 Other 73 (21) 66 (19)
SCLC 61 (15) 48 (12)
Percentages of patients with an NSCLC subtype are based on the number of 
NSCLC patients.
N, number of randomized patients; NSCLC, non–small-cell lung cancer; SCLC, 
small-cell lung cancer.
TABLE 3.  Onstudy Cancer Chemotherapy in Patients with 
NSCLC or SCLC
NSCLC (N = 702)
Denosumab n = 350 Zoledronic Acid n = 352
Total number of agents
 0
 1–2
 3–6
 > 6
68 (19.4)
237 (67.7)
44 (12.6)
1 (0.3)
79 (22.4)
233 (66.2)
40 (11.4)
0 (0.0)
Duration of onstudy 
cancer therapy, mos
 0-<6
 6-<12
 ≥ 12
225 (64.3)
70 (20.0)
55 (15.7)
241 (68.5)
65 (18.5)
46 (13.1)
SCLC (N = 109)
Denosumab N = 61 Zoledronic Acid N = 48
Total number of agents
 0
 1–2
 3–6
 > 6
7 (11.5)
47 (77.0)
7 (11.5)
0 (0.0)
6 (12.5)
37 (77.1)
5 (10.4)
0 (0.0)
Duration of onstudy 
cancer therapy, mos
 0-<6
 6-<12
 ≥ 12
40 (65.6)
13 (21.3)
8 (13.1)
27 (56.3)
17 (35.4)
4 (8.3)
Total number of agents and duration of therapy.
NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer.
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ZA group, with a difference of 2.2 months (KM median = 8.6 
months versus 6.4 months; HR = 0.68; 95% CI = 0.47–0.97; 
p = 0.035) (Fig. 5A). The treatments were associated with simi-
lar overall survival in patients with adenocarcinoma (Fig. 5B).
Adverse Events
Similar patient incidences of overall adverse events 
were reported for patients in both treatment groups (Table 4). 
Patient incidences of serious adverse events were 66.0% for 
denosumab versus 72.9% for ZA, and of fatal adverse events 
were 45.1% versus 47.8%, respectively. The most common 
serious adverse events were tumor progression (16.7% in 
the denosumab group and 15.4% in the ZA group), dyspnea 
(9.6% in each group), respiratory failure (6.9% and 7.8%), 
metastases to the central nervous system (6.7% and 8.1%), and 
pneumonia (6.2% and 6.3%). The most common fatal events 
were tumor progression (15.3% in the denosumab group and 
12.7% in the ZA group), respiratory failure (4.7% and 6.1%), 
metastases to the central nervous system (2.0% and 3.0%), 
general deterioration of physical health (2.0% and 2.8%), and 
dyspnea (2.2% and 1.8%). Hypocalcemia was experienced by 
8.6% of patients in the denosumab group and by 3.8% in the 
ZA group; less than 1% of each group experienced ONJ.
DISCUSSION
Lung cancer is a common malignancy and is typi-
cally aggressive, with poor survival rates after the disease 
has metastasized to other sites.2 This post hoc analysis of a 
large subgroup of patients with metastatic lung cancer showed 
denosumab treatment significantly improved overall survival 
as compared with ZA. These results suggest that denosumab 
may have an additional effect on this disease other than the 
previously demonstrated bone-protective effects.18
Explanations for the possibly longer survival with deno-
sumab treatment in these lung cancer patients include both 
indirect and direct effects on tumor cells. An indirect effect 
may derive from the symbiotic relationship between tumor 
FIGURE 1.  Patient disposition at the time of the primary 
analysis.
FIGURE 2.  Overall survival in patients with any lung cancer. 
KM, Kaplan–Meier.
FIGURE 3.  Overall survival in patients with and without visceral metastases. KM, Kaplan–Meier; HR, hazards ratio; CI, confi-
dence interval.
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cells and the bone marrow microenvironment, in which both 
bone destruction and tumor growth are promoted. In this rela-
tionship, tumor cells secrete various factors that stimulate pro-
duction of RANKL.13 The increased expression of RANKL 
in the tumor environment leads to increased formation, 
activation, and survival of osteoclasts and results in osteolytic 
lesions.19 Osteolysis then results in the release of growth fac-
tors derived from bone.13,20 These growth factors increase the 
production of parathyroid hormone-related protein or pro-
mote tumor growth directly.13 Bone destruction increases local 
extracellular calcium concentrations, which have also been 
shown to promote tumor growth and the production of para-
thyroid hormone-related protein.20 Denosumab may indirectly 
affect skeletal tumor progression by targeting osteoclasts and 
disrupting this interaction between tumor cells and the bone 
microenvironment. RANKL inhibition has been shown to 
reduce bone lesions/osteolysis and skeletal tumor burden in a 
model of NSCLC21 and to enhance antitumor efficacy of other 
therapies on skeletal tumors.22,23
Another hypothesis is that denosumab may improve 
survival by directly inhibiting RANKL on RANK-expressing 
tumor cells, which has been demonstrated for breast cancer 
cells in vivo24 and for a number of tumor cell lines (including 
FIGURE 4.  Overall survival in patients with NSCLC or SCLC. NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer; 
KM, Kaplan–Meier; HR, hazards ratio; CI, confidence interval.
TABLE 4.  Patient Incidence of Adverse Events
Event n (%) Denosumab 
N = 406
Zoledronic Acid 
N = 395
All adverse events 393 (96.8) 377 (95.4)
Serious adverse events 268 (66.0) 288 (72.9)
Fatal adverse events 183 (45.1) 189 (47.8)
Adverse events of interest
 Hypocalcemia 35 (8.6) 15 (3.8)
 Osteonecrosis of the jaw 3 (0.7) 3 (0.8)
N, number of patients who received ≥ 1 dose of active study medication.
FIGURE 5.  Overall survival in patients with non–small-cell lung cancer by histological type. KM, Kaplan-Meier; HR, hazards 
ratio; CI, confidence interval.
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lung cancer cells) in vitro.25 RANKL inhibition may have a 
direct antineoplastic effect on lung cancer cells via apoptosis 
or antimigration activity.26
In our study, denosumab was also associated with 
improved overall survival in lung cancer patients with visceral 
metastases, which commonly determine the pace of disease 
progression and death. This observation may point toward 
potential effects of denosumab beyond the skeleton. Indeed, 
preclinical evidence indicates that RANKL inhibition can 
reduce distant metastasis, and that this effect is potentially 
independent of osteoclast inhibition. In models using mouse 
mammary tumor virus neu transgenic mice, RANKL inhibi-
tion significantly decreased spontaneous lung metastases.24 
Another study27 showed that mouse mammary tumor virus 
neu mice crossed with RANK heterozygotes had decreased 
incidence of lung metastases; pharmacological blockade of 
RANKL had a similar effect. Conversely, lung metastases 
were increased upon systemic RANKL exposure. Preclinical 
investigations are underway to confirm whether RANKL inhi-
bition may exert antitumor activity via indirect (via osteoclast 
inhibition) and/or direct (e.g., apoptosis, inhibition of cancer 
migration/invasion) effects on lung cancer cells.
Several baseline variables, including age and ECOG 
status, did not account for the increase in overall survival 
observed in denosumab-treated patients. However, other 
patient characteristics may play a role in survival. For example, 
bone turnover markers can provide insight into the aggressive-
ness of metastases. N-telopeptide of type I collagen (NTX) 
is a sensitive marker of osteolysis. High baseline NTX lev-
els were correlated with increased SRE risk in a retrospective 
analysis of 382 patients with NSCLC and bone metastases.9 
When compared with placebo, ZA reduced the relative risk of 
death in patients with high baseline NTX in that retrospective 
analysis.9 As denosumab is a more potent inhibitor of bone 
turnover, better outcomes may also be expected.
As observed in the analysis of adverse events in the full 
study population,18 hypocalcemia occurred more frequently 
with denosumab than with ZA. This observation is consis-
tent with the more potent antiresorptive effect of denosumab. 
The rate of serious adverse events was similar in both arms 
(approximately 66% for denosumab versus 73% for ZA). 
Overall, the treatments had similar safety profiles, including 
similar rates of ONJ. No additional adverse events or differ-
ences in adverse event rates were observed in the lung cancer 
subgroup compared with the full study population.
Subcutaneous drug administration offers advantages 
over intravenous administration. It is associated with fewer 
acute phase reactions and does not require renal monitoring. 
As observed in the analysis of adverse events in the full study 
population, approximately 15% of the ZA group had acute 
phase reactions compared with 7% of the denosumab group. 
In addition, approximately 11% of patients in the ZA group 
had renal adverse events, despite dose adjustments and dose 
withholding for renal impairment, per the ZA label, compared 
with 8% of patients in the denosumab group.
In summary, in this post hoc exploratory analysis of a 
large subgroup of patients with lung cancer and bone metas-
tases, denosumab treatment was associated with significantly 
improved overall survival compared with ZA. The strength of 
these data lies in the large number of patients evaluated and 
the consistency of the observation across subsets, whereas 
the limitation of these data is the retrospective nature of the 
analysis. These findings warrant further prospective clinical 
investigation.
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